BIOGEN INC. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31)
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31) of $7.16 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-03.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax · last filed 2012-02-03
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2012-01-31) for fiscal 2011 was $7.16M, a 26.50% increase from fiscal 2010.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2012-01-31) for fiscal 2010 was $5.66M, a 50.59% increase from fiscal 2009.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2012-01-31) for fiscal 2009 was $3.76M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | $7.16M 10-K · filed 2012-02-03 |
| 2010-12-31 | $5.66M 10-K · filed 2012-02-03 |
| 2009-12-31 | $3.76M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |